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Abstract
Chronic Lymphocytic Leukemia (CLL), the most prevalent adult leukemia in western countries, which is 
highly heterogeneous with a very variable clinical outcome. Emerging evidence indicates that the stromal tumor 
microenvironment (STME) and stromal associated genes (SAG) play important roles in the pathogenesis and 
progression of CLL. However, the precise mechanisms by which STME and SAG are involved in this process 
remain unknown. In an attempt to explore the role of STME in this process, we examined the expression levels 
of stromal associated genes using gene expression profiling (GEP) of CLL cells from lymph nodes (LN) (n=15), 
bone marrow (BM) (n=18), and peripheral blood (PB) (n=20). Interestingly, LUM, MMP9, MYLK, ITGA9, CAV1, 
CAV2, FBN1, PARVA, CALD1, ITGB5 and EHD2 were found to be overexpressed while ITGB2, DLC1 and ITGA6 
were under expressed in LN-CLL compared to BM-CLL and PB-CLL. This is suggestive of a role for LN-mediated 
TME in CLL cell survival/progression. Among these genes, expression of MYLK, CAV1 and CAV2 correlated with 
clinical outcome as determined by time to first treatment. Together, our studies show that members of the stromal 
signature, particularly in the CLL cells from lymph nodes, regulate CLL cell survival and proliferation and thus 
leukemic progression.
Orimo et al. have reported that stromal fibroblasts present in invasive 
human breast cancer promote tumor growth and angiogenesis through 
elevated SDF/CXCL12 secretion [7]. Together, these reports advocate 
the importance of complex interactions between CLL and other tumor 
cells with their microenvironment for increased proliferation leading 
to disease progression. In B cells, such interactions involve cytoskeletal 
changes possibly mediated by stromal microenvironment leading to 
enhanced B cell activation by BCR clustering [8,9]. Similar mechanisms 
may impose altered cytoskeletal changes in CLL cells leading to better 
survival and proliferation. Therefore, identification of molecular 
network involved in modification of LN microenvironment by CLL 
cells will lead to a better understanding of the disease. In an attempt 
to understand the molecular basis of stromal associated regulation of 
CLL progression and its prognostic implication we performed a gene 
expression profiling (GEP) of CLL cells from PB, BM and LN. We 
also performed transcriptome analysis of PB-CLL cells from patients 
with good versus poor prognosis to identify stromal gene signatures 
associated with disease aggressiveness. We identified two genes, MYLK 
and CAV2, whose transcript and protein expression is upregulated in 
patients with poor prognosis than good prognosis and significantly 
associated with patient’s outcome. 
Keywords: Stromal tumor microenvironment; Stromal gene 
signature; CLL
Introduction
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous, 
incurable B cell malignancy affecting elderly population in the western 
world. Emerging evidence suggest that CLL cells depend on complex 
communications with their microenvironment for survival. Due to an 
overt dependence of CLL cells on these interactions, their survival is 
greatly reduced when cultured in vitro by themselves. We and others 
[1,2] have shown that the tumor microenvironment (TME) in lymph 
nodes (LN) provide pro-survival/proliferation signals to CLL cells 
and induces host immune suppression [3]. Furthermore, prolonged 
survival of CLL cells in the proliferation centers in bone marrow 
(BM) and in LNs is mediated by several stromal micro-environmental 
(STME) cues; however, the precise nature of these interactions remains 
ambiguous. LN microenvironment is comprised of stromal and other 
cells along with the associated extra cellular matrix. Extra cellular 
matrix is comprised of proteoglycans, integrins, hyaluronic acid and 
reticular network. On the other hand, stromal and other cells in the 
lymph nodes represented by lymphatic endothelial cells, mesenchymal 
cells, T cells, follicular dendritic cells and monocytes-derived nurse-
like cells have been shown to enhance CLL cell survival [4]. The STME 
helps them to escape from therapy resulting in increased relapse 
rate in CLL patients [4]. Once the tumor cells colonize in LNs, they 
shape their microenvironment to support their own survival and 
growth. This partly involves the activation of immune tolerance 
genes in CLL cells [3]. Recently Garcia-Munoz et al. have suggested 
that immunoglobulin gene mutated CLL cells in the LN, acquire 
self-reactivity for auto antigens while being tolerized with receptor 
editing [5]. As a consequence, the normal function and proliferation of 
nonmalignant B cells in the TME are also affected [5]. Lenz et al. have 
eloquently demonstrated that survival of diffuse large B cell lymphoma 
following treatment is influenced by the differences in immune cells, 
fibrosis and angiogenesis in the TME [6]. This conclusion was based 
on the analyses of stromal gene signatures in large B cell lymphomas. 
Citation: Shukla A, Chaturvedi NK, Ahrens AK, Cutucache CE, Mittal AK, et al. (2013) Stromal Tumor Microenvironment in Chronic Lymphocytic 
Leukemia: Regulation of Leukemic Progression. J Leuk 1: 113. doi:10.4172/2329-6917.1000113
Page 2 of 9
Volume 1 • Issue 2 • 1000113
J Leuk 
ISSN: 2329-6917 JLU, an open access journal 
Methods
CLL patient information
Using an Institutional Review Board approved-protocol and 
informed consent, CLL samples were obtained from patients. PB 
(n=20), BM (n=18) and LN (n=15) samples from 53 CLL samples 
were collected from 37 different patients. In addition, to validate the 
results, additional peripheral blood CLL samples from 20 patients and 
another 15 patients with good prognosis (n=7) and poor prognosis 
(n=8) patient peripheral blood samples were also used. In this study, 
we included CLL patients who are untreated and who did not receive 
any treatment for six months prior to sample collection. For control, B 
cells from age matched normal donors were obtained. 
The clinical information on these 72 patients are provided in tables 
1a-1c.
CLL cells isolation and characterization
All CLL samples for this study were obtained using an UNMC 
Institutional Review Board approved protocol. CLL cells were 
isolated from PB and BM using density gradient centrifugation with 
lymphocyte separation medium, LymphoPrep, followed by negative 
selection using magnetic bead separation method as needed [10,11]. 
Frozen LN samples were obtained from the UNMC tissue bank. CLL 
cells were localized on frozen LN samples using immunohistochemistry 
by staining CD19 and CD5 positive cells. Fifteen to twenty sections of 
8-10 micron thickness were made at 4°C and fixed immediately by ice-
cold acetone and stained with cresyl violet (LCM Staining Kit, Ambion, 
TX, USA) for 30 seconds. These cells were micro dissected for RNA 
isolation [2]. For CLL cells isolated from PB and BM, the purity was 
tested by flow cytometry using the combination of CD3-FITC, CD19-
PE, CD5-PE, CD38-PE and CD19-FITC (BD Biosciences, San Jose, 
CA, USA).
Clinical characterization of CLL patient
Patients with high CD38 positive, bulky lymphadenopathy, 
chromosome 11q deletion, 17p deletion and trisomy 12, unmutated 
IgVH and shorter time to first treatment were considered as a poor 
prognosis patient, whereas patients with only 13q deletion or normal 
karyotype, mutated IgVH and longer time to treatment were considered 
as a good prognosis patient [11,12]. 
Microarray analysis
RNA from CLL cells was extracted using TRIzolTM (Invitrogen, 
Grand Island, NY, USA) as per the manufacturer’s instruction. Gene 
expression profiling was performed using a DNA microarray chip 
(MWG Biotech, Germany, Human 30K oligo set B) consisting of a 50-
mer oligonucleotide representing 10,000 different genes. cDNAs were 
obtained from RNA using Stratagene manufacturer’s instructions. 
The hybridized slides were scanned and images were collected by an 
Axon 4000B scanner (Axon Instruments, Grand Terrace, CA, USA). 
Differentially expressed stromal signature genes were identified using 
significance analyses of microarray (SAM).
Transcriptome analysis
RNA from peripheral blood B cells of seven good prognosis 
CLL patients and eight poor prognosis CLL patients was isolated as 
mentioned above. The mRNA levels of stromal related genes with 
significant p value were compared between good and poor prognosis 
patients. The RNA sequencing was done at the UNMC Next Generation 
Sequencing Core facility using Illumina HiSeq 2000 sequence analyzer. 
RNA sequence alignment was done by TopHat alignment software; 
this was followed by Picard processing for removal of duplicates. To 
identify differential gene expression levels among the good versus poor 
prognosis, Cuffdiff method was used. To determine the relative fold 
change the values were normalized with GAPDH. Clinical information 
of these 15 patients is provided in table 1d.
Patients
ID Age Gender Time to treatment 
Fluorescence in-situ
Hybridization Bulky disease CD 38% IgVH Mutation status
PB12 69 M 1 NA No lymphadenopathy 45% NA
PB16 51 M 1 Trisomy 12; 17p-; 13q14- Bulky adenopathy 89% NA
PB22 66 F Never NORMAL No lymphadenopathy 12% NA
PB37 53 M NA NORMAL No lymphadenopathy 4% NA
PB82 79 M 4 Trisomy 12 , 13q14 del BALA 92% Unmutated
PB89 39 M 10 Trisomy 12 (23% - 56%) Mild lymphadenopathy 3% NA
PB90 66 F Never 13q14 del No lymphadenopathy 20% NA
PB96 85 F 1 NORMAL Mild lymphadenopathy 9% NA
PB97 54 F 2 NORMAL Lymphadenopathy 51% NA
PB106 65 M Never 13q null No lymphadenopathy 27% NA
PB107 58 M 2 11q22.3/ATM (96%); 13q14 deletion (96.5%)
LN (axilla, supraclavicular, 
mediastinal ) 1.50% NA
PB109 44 M 0.25 11q22.3/ATM (96%), 13q14 (12%), (14q32 del, 77.5%) LN (neck and axilla) NA NA
PB117 80 M 48 13q14 (87.5% - 96%) IgH (12.5%) BALA (axillary) 32.45% NA
PB121 47 M Never 13q14 (72%) No lymphadenopathy 7% NA
PB124 53 F Never Blood14q32 (35.5%) No lymphadenopathy 11% NA
PB134 57 M 82 13q nullosomy No lymphadenopathy 23% NA
PB141 71 M Never 13q14 (38.5%) No lymphadenopathy 24% NA
PB143 69 F Never 13q14 (53.5%), cyto-N; 13q14 (83%) No lymphadenopathy 12% NA
PB146 76 F 17 11q23 (84.5%), 13q14 (15.5%) No lymphadenopathy 43% NA
PB149 41 M 6 17p- (11%), 13q- (33%), 14q- (12%) LN (neck) 8% NA
Table 1A:  Peripheral Blood CLL patient samples information.
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Clinical correlation of the gene expression levels
The Kaplan Meier analysis log-rank test was used to analyze clinical 
correlation of gene expression levels or clinical parameters with time 
to first treatment. Time to treatment is the interval in months between 
diagnosis and initiation of the first treatment in months among the 
CLL patients. In some cases the CLL cells used in the study were 
classified based on cytogenetic chromosomal abnormality, where CLL 
cells 13q deletion and normal karyotype were considered as good 
prognosis and CLL cells with 11qdel, trisomy 12 and 17p deletion 
as poor prognosis group. Also CD38 low (less than 30% positive) or 
immunoglobulin gene mutation and CD38 high (more than 30%) or 
unmutated immunoglobulin gene were also grouped as good and poor 
prognosis, respectively.
Western blotting
The expression of MYLK, EHD2, DLC1 and CAV1 in B cells from a 
normal healthy donor, five good prognosis CLL patients and five poor 
prognosis CLL patients were determined using western blot analyses. 
50 µg of protein was loaded on 10% SDS-PAGE gel, which was 
separated by electrophoresis, and blotted on PVDF membrane. In brief, 
the membrane was incubated with primary antibodies of MYLK and 
DLC1 (Santa Cruz Biotechnologies, Dallas, TX, USA), CAV1 (Abcam, 
Cambridge, MA, USA), EHD2 (homemade antibody was kindly 
provided by Dr. Hamid Band, UNMC) and β-actin (Sigma Aldrich, 
St. Louis, MO, USA). This was followed by incubation of membranes 
with appropriate secondary antibodies and blot was developed using 
Enhanced Chemiluminescence, Pierce ECL Western Blotting Substrate 
(Thermo Scientific, Waltham, MA, USA). 
Statistical analysis
For the identification of differentially expressed genes, a significant 
analysis of microarray (SAM) was used. To identify the tissue specific 
gene signatures, analysis was performed using random variance t-test 
Table 1B: Lymph Nodes CLL patient samples information.
Patients
ID Age Gender
Time to 
treatment 
Fluorescence in-situ
Hybridization Bulky disease CD 38%
IgVH Mutation 
status
LN11 59 M 1 TRISOMY 12 (47%); 14q32 (25%), then 12% n 13% after that 17p del
Yes, diffuse abdominal, axilla, 
groin, neck LN 80% Unmutated
LN34A 74 M 2 11q23 from 13qdel BALA 63% NA
LN34B 74 M 2 11q23 from 13qdel BALA 63% NA
LN40A 49 M 1 13q14 (68.5%),both11.5%,null 13.5%, then 17p13 in LN; BALA 92% Unmutated
LN40B 49 M 1 13q14 (68.5%),both11.5%,null 13.5%, then 17p13 in LN; BALA 92% Unmutated
LN59 62 F 108 NA Lymphadenopathy  NA
LN64 72 F 48 17p13 *                            Lymphadenopathy  NA
LN66A 61 F 11 11q22.3/ATM (78%), 13q14 (89%), 17p13.1 (3 copies in 46.3%)           BALA 84% Unmutated
LN66B 61 F 11 11q22.3/ATM (78%), 13q14 (89%), 17p13.1 (3 copies in 46.3%)           BALA 84% Unmutated
LN67 42 M 1 11q23, 13q14           BALA 21% Unmutated
LN82 79 M 4 Trisomy 12 , 13q14 del BALA 92% Unmutated
LN83A 29 M 22 11q23 deletion (92%), 14q32 (64.5%) BALA 98% Unmutated
LN83B 29 M 23 11q23 deletion (92%), 14q32 (64.5%) BALA 98% Unmutated
LN93 50 M 1 14q- BALA 52% NA
LN149 41 M 6 17p- (11%), 13q- (33%), 14q- (12%) LN (neck) 8% NA
Table 1C: Bone marrow CLL patient samples information.
Patients ID Age Gender Time to treatment Karyotype Bulky disease CD 38% IgVH Mutation status
BM12 69 M 1 NA No lymphadenopathy 45% NA
BM16 51 M 1 Trisomy 12; 17p-; 13q14- Bulky adenopathy 89% NA
BM32 65 F NA 13q14 Lymphadenopathy 34% NA
BM34 74 M 2 11q23 from 13qdel Lymphadenopathy 63% NA
BM37 53 M NA NORMAL No lymphadenopathy 4% NA
BM67 42 M 1 11q23, 13q14           BALA 21% Unmutated
BM74 55 M Never 13q13 deletion No lymphadenopathy 5% Mutated
BM83 29 M 22 11q23 deletion (92%), 14q32 (64.5%) BALA 98% Unmutated
BM89 39 M 10 Trisomy 12 (23% - 56%) Mild lymphadenopathy 3% NA
BM106 65 M Never 13q null No lymphadenopathy 27% NA
BM117 80 M 48 13q14 (87.5% - 96%) IgH (12.5%) BALA (axillary) 32.45% NA
BM120 65 M 3 14q- LN (neck) 34% NA
BM122 50 M 17 various del, 17p del, 20q-, 7p- No lymphadenopathy 33.50% NA
BM124 53 F Never blood- normal in BM-14q32 (35.5%) No lymphadenopathy 11% NA
BM152 60 M Never 13q- (48%) No lymphadenopathy NA NA
BM163 70 M Never 13q null (24%), 13q- (46%) No lymphadenopathy 23% NA
BM166 52 M Never NORMAL LN(axillary) 28% NA
BM168 56 F Never 13q null (11%), 13q del (66%) mild LA NA NA
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with p-value of 0.01 and false discovery rate (FDR) of 0.08. The most 
of analyses were performed at p<0.05 and FDR<0.25, unless specified 
otherwise. The Kaplan-Meier method using log-rank test was used to 
study the association of gene expression or clinical parameter with the 
clinical outcome as done previously [13].
Results
Supervised cluster analyses of differential expression of 
stromal signature I and II associated genes in primary CLL 
cells
Figure 1 shows a supervised cluster analyses of the differential 
expression of stromal signature I and II genes in CLL cells isolated from 
peripheral blood (PB), bone marrow (BM) and lymph nodes (LN) from 
patients in comparison to each other and with normal B cells from 
healthy donors (nB). In the case of stromal signature I, 119 genes were 
analyzed. There were in total 47 genes that are differentially expressed. 
Among these 47 genes, 30 genes were overexpressed and 17 genes 
were under expressed compared to each other. Among the 30 genes 
overexpressed, based on the transcript levels, we divided them into the 
categories of high (11 genes), medium (8 genes) and low (11 genes) 
expressing genes based on the fold change in their expression compared 
to reference as shown in table 1. In this Stromal I gene signature, these 
differentially expressed genes are associated with extracellular matrix, 
cytoskeleton maintenance, cell migration, and biosynthesis of collagen. 
We have recently shown that the CLL cells in the LNs induce immune 
tolerance against themselves to facilitate their uninhibited growth [2]. 
Interestingly, many of the genes including SERPINH1, SERPINF1, 
FBN1, APOE, PTGDS, LUM, CALD1 and MYLK were significantly 
overexpressed in CLL cells in the LNs compared to BM, PB and nB.
In the case of stromal II genes, there were a total of 35 genes; of 
these, 22 genes were differentially expressed genes. Among these 22 
genes, 14 genes were overexpressed and 8 genes were under expressed 
in CLL cells compared to normal B cells. Among the overexpressed 
genes, 7 genes had high expression levels and 7 genes had medium 
expression levels and there were no genes in which expression was 
relatively low compared to other genes in the category. Stromal 
signature II shows the mRNA level of genes which are associated with 
intracellular compartment: EHD2, SDF1, PTPRB, CAV2 and CAV1 
[14] were overexpressed, whereas DLC1, which is a known tumor 
Table 1D: Patients Clinical information used for Transcriptome.
Patients ID Age Gender Time to treatment 
Fluorescence in-situ
Hybridization Bulky disease CD 38%
IgVH Mutation 
status
CLL 3 61 F 98 TRISOMY 12 (65.5%) No lymphadenopathy 83% Unmutated
CLL 11 59 M 1 TRISOMY 12 (47%); 14q32 (25%), then 12% n 13% after that 17p del
Yes, diffuse abdominal, axilla, 
groin, neck LN 80% Unmutated
CLL 29 55 F 69 11q23- (91%);13q14 mono (95.5%),13q14(60%); 14q32 (65.5%) BALA 17% Unmutated
CLL 30 55 F 12 Trisomy 12 (70.5%) Lymphadenopathy 55% Unmutated
CLL 34 74 M 2 11q23 from 13qdel BALA 63% NA
CLL 40 49 M 1 13q14 (68.5%),both11.5%,null 13.5%, then 17p13 in LN; BALA 92% Unmutated
CLL 79 62 M 15 11q22.3 (78%), 13q14 (53.5%), null13q14 (34%) No lymphadenopathy 23% Unmutated
CLL 82 79 M 4 Trisomy 12 , 13q14 del BALA 92% Unmutated
CLL10 49 F Never Normal No lymphadenopathy 6% Mutated
CLL 13 83 M 1 Normal No lymphadenopathy NA NA
CLL 19 56 F Never 13q14- No lymphadenopathy NA NA
CLL 75 34 M 96 Normal No lymphadenopathy 3% Mutated
CLL 100 70 F Never 13q14 No lymphadenopathy 18% NA
CLL 108 63 M Never 13q14 and 14q32 rearrangement No lymphadenopathy 9% NA
CLL 164 64 F 12 Normal No lymphadenopathy NA NA
Table 2:  Expression of the stromal signature 1 and 2 genes in LN-CLL compared to PB-CLL, BM-CLL and normal B-cells in gene microarray analysis. The Overexpressed 
genes were categorized into high (>2 fold), medium (>1.5 fold) and low (~1.5 fold) higher expressed genes compared to PB-, BM-CLL and normal B-cells.
Signature Overexpressed Genes Under expressed 
GenesHigh Medium Low
Stromal 1
Apoe
Clu
Lum
Mmp9
Mylk
Robo1
Wnt2b
Cxcl14
Pcolce
Serpinf1
Cox7a1
Aebp1
Col4a4
Cyr61
Fbn1
Lama4
Parva
Ptgds
Evc
Adamdec1
Cald1
Chn1
Ctgf
Ctsk
Dzip1
Edg2
Itgb5
Ppa2b
Rarres1
Sparc
Adra2a
Angpl2
Cebpa
Cspg2
Cyp27a1
Dlc1
Edil3
Gja1
Islr
Maff
Pkd2
Ptprf
Rab32
Rtn1
Ceecam
Fap
Itgb2
Stromal  2
Itga9
Saa1
Cav1
Cav2
Fabp4
Ced6
Ehd2
Col5a3
Lamb1
Prrg1
Sh3d5
Pa2ga
Sparcl1
Aqp1
Sema4c
Dlc1
Sdf-1
Procr
Apm1
Kdr
Itga6
Rbp4
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Figure 1: Differential expression of stromal signature I and II associated genes in primary CLL cells: GEP showing differential expression of Stromal Signature I & 
II in cells isolated from peripheral blood (PB), bone marrow (BM) and lymph nodes (LN) from CLL patients in comparison with normal B cells from healthy donors 
(nB). Stromal Signature I and II showing the differential gene expression in extra cellular matrix compartment and cellular components of CLL patients and healthy 
donors.  mRNA level of some cytoskeleton related genes like MYLK, APOE and PTGDS from stroma I, EHD2, CAV2 and CAV1 from stroma II were high, whereas 
tumor suppressor genes like DLC1 was down regulated in both stroma I & II. 
suppressor [15], was under expressed in both stromal signatures I and 
II. 
Validation of differential expression using transcript levels of 
selected stromal genes in CLL cells from PB, BM and LN
We confirmed the differential expression of selected genes by 
evaluating the mRNA levels of each gene. In these analyses, we either 
compared the gene expression to the expression levels in normal B 
cells, and/or compared to normal B cells as well as to CLL cells from 
PB, BM and LNs. Figure 2 shows the results of these analyses. There was 
an increased expression of MYLK and decreased expression of DLC1, 
CSPG2/VCAN and ITGB2 in CLL B cells (Figures 2A-2D). Further 
comparison of these three and additional genes with CLL cells from 
PB, BM and LN and normal B cells showed there was a significantly 
increased expression (p<0.05) of MYLK, EHD2, CAV2 in CLL cells 
from the LNs compared other cells in these analyses group (Figure 
2E-2G). In contrast, the expression of DLC-1 and CSPG2/VCAN were 
significantly decreased (p<0.05) in the CLL cells from the lymph nodes 
compared to rest of the cells in this analyses group (Figure 2H and 2I). 
Validation of differential expression of selected genes at 
protein levels using western blotting
As further validation for higher expression of MYLK, CAV1 and 
EHD2 and lower expression of DLC1 seen in the transcript analyses, 
we performed comparison of protein expression on the basis of disease 
progression. The evaluation of protein levels of these genes was done 
using PB CLL cells from five patients with good prognosis and CLL 
cells from five poor prognosis and normal donor B cells. Figure 3 shows 
the results of these analyses. There was an increased expression of 
MYLK1, EHD2 and CAV2 in all five CLL patients with poor prognosis 
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Figure 2: Expression levels of stromal genes in CLL cells from PB, BM and LN: Comparison of mRNA expression of (A) myosin light kinase (MYLK), (B) versican 
(VCAN), (C) deleted in liver cancer (DLC1), (D) Integrin, Beta 2 (ITGB2) in PB isolated B cells from 8 healthy donors and 20 CLL patients. mRNA expression 
comparison of (E) myosin light kinase (MYLK), (F) EH domain containing 2 (EHD2), (G) caveolin 2 (CAV2), (H) deleted in liver cancer (DLC1) and (I) versican 
(VCAN) in B cells from PB of 8 healthy donors and B cells from PB, BM and LN samples from 37 CLL patients samples. Student t-TEST was applied to determine 
the statistically significance among the normal healthy donors and CLL patients. “*” determine p value of ≤ 0.05. The relative expression was normalized by GAPDH. 
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Figure 3: Analysis for protein expression: Expression of selected proteins in normal B and CLL cells from PB of 5 good prognosis and 5 poor prognosis patients 
using western blotting.
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compared to CLL cells from five good prognosis patients, whereas the 
expression levels of DLC1 was significantly higher in good prognosis 
patients compared to CLL cells from poor prognosis patients. In these 
analyses, β-Actin was used as housekeeping gene control. Together 
these analyses confirmed the differential expression these selected 
genes.
Clinical significance of stromal genes
Next, in order to understand the clinical significance of the 
differentially expressed genes, we compared the expression levels of 
expression of stromal signature I associated genes whose transcript 
analysis were statistically significant, namely CEBPA, MYLK, APOE, 
RAB32, PTGDS and WNT2B and levels of expression of stromal 
signature II associated genes, namely DLC1, CAV2, EHD2, SDF1, 
RBP4 and ROBO1, with the time to first treatment in patients. Figure 
4 shows the results of these analyses using Kaplan Meier analyses with 
log-rank test. We have previously shown that high expression CAV1 
correlated with clinical outcomes; also knockdown of CAV1 impaired 
CLL cells to migrate and formation of immune synapse [2]. Among the 
12 genes we evaluated, higher expression of MYLK and CAV2 (Figure 4) 
significantly correlated with poor clinical outcome. Recently Yamasaki 
et al., showed higher expression of CAV2 promotes cell proliferation, 
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Figure 4: Clinical significance of stromal genes:  Clinical correlation of expression levels of stromal signature I associated genes (CEBPA, MYLK, APOE, RAB32, 
PTGDS and WNT2B) and stromal signature II associated genes (DLC1, CAV2, EHD2, SDF1, RBP4 and ROBO1) in CLL patients using Kaplan Meier analyses with 
log-rank test. Among these genes, expression of MYLK, WNT2B, DLC1, EHD2 and CAV2 in stromal signature I and II correlated with clinical outcome as determined 
by time to treatment.
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migration and invasion in renal cell carcinoma [16]. DLC1 is a known 
tumor suppressor and the western blot analysis confirmed the down 
regulation at the protein level which made it interesting to see the 
clinical outcome. However, although not statistically significant, higher 
expression of WNT2B and EHD2 and lower expression of DLC1 
showed clinical correlation (Figure 4). The rest of genes did not show 
clinical correlation with time to first treatment in patients. 
Gene expression levels determined by RNA sequencing
In order to identify additional genes which are associated with 
extracellular matrix we did comparative analysis of differential gene 
expression in Good Prognosis CLL and Poor prognosis CLL using 
RNA transcriptome analysis. The mRNA level of genes encoding for 
cell surface proteoglycan and glycoprotein those also associated with 
stromal signature (Table 2) I & II as mentioned above like VCAN and 
CD93 were 50 and 20 fold up-regulated respectively; inflammatory 
related cytokines associated genes like IL8, CXCL1 and CXCL3 were 40, 
77 and 111 fold up-regulated respectively in good prognosis; and SPP1 
and SERPINB2 were 955 and 1271 fold higher than poor prognosis 
respectively. Among these differentially expressed genes identified in 
our transcriptome analyses, expression levels of proteins of selected 
extracellular matrix genes were evaluated using Western blot analyses. 
There was a significantly increased protein level of VCAN, SPP1 and 
SERPINB2 in CLL cells from good prognosis compared to CLL cells 
from poor prognosis patients (Figure 5). Thus these results validated 
the differential expression of certain extracellular matrix associated 
genes as identified in transcriptome analyses. 
Discussion
In this report, we have studied the nature of expression of 
stromal signature genes in CLL cells from PB, BM and LNs. CLL 
cells, particularly in the patient’s body, proliferate and survive for a 
long time; however, they do not survive long once they are removed 
from the body, suggesting the role of in vivo microenvironment. 
Evidence from literature indicates that CLL cell’s inability to survive 
in vitro is due to lack of complex interactions between CLL cells and 
the surrounding microenvironment. We and others [1,2] have shown 
that the tumor microenvironment (TME) in the LN provides pro-
survival/proliferation signals to CLL cells leading to the formation of 
proliferation centers (PCs) with varied sizes from small to extensively 
large. It is previously demonstrated that CLL cells at the tissue sites such 
as LNs induce host immune suppression via differential expression of 
tolerogenic genes reported earlier in T cell malignancy [17]. Based on 
our previous studies, we believe that the CLL lymph node induced 
host immunosuppression significantly contributes to the leukemic 
progression in CLL patients [2]. However, the precise mechanism of 
the process and particularly the role played by stromal genes in CLL 
in the tissue microenvironment is not known. Therefore, the current 
study was undertaken.
Lenz et al. [5] have reported that in the case of diffuse large B 
cell lymphoma, stromal signature predicted the clinical outcome. In 
the present study, differentially expressed genes from both stromal I 
and II signatures were involved in the poor prognosis CLL with LN 
involvement. For example in the case of one of the overexpressed genes 
MYLK, a member of the stromal signature I, higher expression of this 
gene was correlated with poor prognosis. Similarly, CAV1 [2] and 
CAV2 members of the stromal II signature are overexpressed in CLL 
cells from LN and correlated with poor clinical outcome in patients. 
Furthermore, in the current study, the higher expression of CAV2 
is correlated with poor prognosis. In addition, Myosin Light Chain 
Kinases (MLCKs) are a group of proteins found in smooth muscle and 
phosphorylates myosin II regulatory light chains at Ser19, allowing 
myosin cross bridges to bind to actin filaments and initiate contraction 
[18,19]. Interestingly, we have recently reported [2] that over 
expression of CAV1 in CLL cells in the lymph nodes might be involved 
in inhibiting immune synapse formation via regulating the actin 
polymerization. This leads us to speculate that MYLK might be involved 
in the CAV1 mediated inhibition of immune synapse formation of CLL 
cells in the LNs. Further, in-depth analyses are needed to confirm the 
role for MYLK in the CAV1 mediated immunosuppression specifically 
inhibition of immune synapse formation. In this regard, we also see the 
over expression of CAV2, associated with poor prognosis in CLL, might 
also be involved in interacting directly with G-protein alpha subunits 
and thus functionally regulate their activity through phosphorylation 
of Ser-36 to modulate mitosis in CLL cells. This might be through being 
a positive regulator of cellular mitogenesis of the MAPK signaling 
pathway.
Our transcriptome analyses of extracellular matrix associated 
genes revealed an over expression of VCAN, SPP1 and SERPINB2 in 
CLL cells from good prognosis patients. Although we do not know 
the significance of the elevated expression of these genes in CLL 
biology it is possible that these genes interact with CAV1 and CAV2 in 
regulating immune response towards CLL, this need to be addressed to 
understand the role of these overexpression genes.
In summary, differential gene expression (Table 3) of stromal 
signature I and II highlighted cytoskeleton associated genes like MYLK, 
CAV1, CAV2 and EHD2 which were significantly upregulated in CLL 
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Figure 5: Validation of differentially expressed extracellular matrix associated genes in good and poor prognosis CLL samples using analyses for protein expression: 
Expression of selected extracellular matrix associated proteins in CLL cells from PB of 4 good prognosis and 4 poor prognosis patients using western blotting method.
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cells from patient’s LNs. Expression levels of stromal associated genes 
MYLK, DLC1, WNT2B, EHD2 and CAV2 correlated with clinical 
outcome. Thus, our results suggest that STME provides survival signals 
to CLL cells and facilitates the resistance to therapy which might be 
leading to leukemic progression. 
In addition our transcriptome analyses showed several genes 
associated with extracellular matrix significantly upregulated in good 
prognosis. These results lay the foundation for in-depth analyses of 
these genes to elucidate the functional significance at the mechanistic 
levels of the differential expression of the relevant genes.
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